About ArsenalBio
ArsenalBio is a Healthcare company based in San Francisco (United States) founded in 2019 by Ken Drazan. ArsenalBio has raised $631.16 million across 3 funding rounds from investors including Kleiner Perkins, T. Rowe Price and University of California. The company has 178 employees. Its chief executive, as recorded, is Ken Drazan. ArsenalBio offers products and services including AB-4000 Series. Its focus areas include Life Sciences, Cell Therapy, Adoptive Cell Therapy and T-Cell. Its legal entity is Arsenal Biosciences, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Developer of immune cell therapies. The company develops programmable immune cell therapies using cloud computing, genome engineering, and synthetic immunology technologies.
- Headquarters San Francisco, United States
- Employees 178
- Founders Ken Drazan
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website arsenalbio.com
- Social LinkedIn X
- Legal Name Arsenal Biosciences, Inc.
- Total Equity Funding$631.16M (USD)
in 3 rounds
- Latest Funding Round$325.35M (USD), Series C
Jul 2024
- InvestorsKleiner Perkins
& 22 more
- Employee Count178
Products & Services of ArsenalBio
ArsenalBio offers a comprehensive portfolio of products and services, including AB-4000 Series.
Advanced T cell therapies designed to target and treat solid tumors effectively.
Funding Insights of ArsenalBio
ArsenalBio has successfully raised a total of $631.16M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $325.35 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $631.16M
- Total Rounds 3
- Last Round Series C — $325.35M
- First Round $85M
(Oct 2019)
- Investors Count 23
All 3 funding rounds of ArsenalBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $325.35M | Series C | – | Arch Venture Partners, Milky Way Investments Group | |
| Sep 2022 | $220.81M | Series B | – | Bristol-Myers Squibb, Westlake Village Biopartners | |
| Oct 2019 | $85M | Series A | – | Westlake Village Biopartners, Kleiner Perkins |
23 investors in total: 23 institutional.
Investors in ArsenalBio
ArsenalBio has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, T. Rowe Price and University of California.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital is invested in biopharmaceutical and healthcare firms. | regeneronventures.com | Tarrytown, United States | ||
Venture capital arm of Nvidia | nventures.ai | Santa Clara, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Westlake BioPartners is engaged in biotech venture capital investment. | westlakebio.com | Westlake Village, United States | ||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Venture capital funding is provided for technology and healthcare companies. | hitachi-ventures.com | Munich, Germany | ||
LumaGroup is focused on investing in life sciences innovations. | lumagroup.com |
Investor details for ArsenalBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ArsenalBio
124 people are tracked at ArsenalBio (36 in leadership, 16 in board & advisors, 72 in team); the tracked headcount is 178.
| Name | Role | Group |
|---|---|---|
Ken Drazan | Co-Founder & CEO | Leadership |
Angela Boroughs | Associate Director, Immunology | Leadership |
Robby Moot | Director Of Discovery Cell Engineering | Leadership |
Maike Schmidt | Vice President Translational Sciences | Leadership |
Alice Chang | Associate Director | Leadership |
Haixia Wang | Head Of Analytical Development | Leadership |
Christopher Murriel | Vice President, Pre-clinical Pharmacology | Leadership |
Tim Sirichoke | Chief Technical Operations Officer | Leadership |
Bee Nguyen | Chief People Officer | Leadership |
Andrea Liu | Director, Molecular Biology | Leadership |
Jenny Wu | Senior Director Human Resources | Leadership |
Joe Dudek | Director Quality Operations | Leadership |
Jun Feng | Sr Director, Preclinical Development | Leadership |
Levi Gray-Rupp | Senior Director | Leadership |
Amanda Ceja | Senior Administrative Business Partner | Leadership |
Nick Haining | Chief Scientific Officer | Leadership |
Jonathan Chen | Associate Director Of Accounting | Leadership |
Billy Wong | Assoicate Director Of Vivarium Operation | Leadership |
Luke Cassereau | Director | Leadership |
Michelle Fan-Port | VP Translational Biometrics | Leadership |
104 more people are available in the full profile.
Complete people profiles for ArsenalBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ArsenalBio
3 dated milestones of ArsenalBio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded ArsenalBio is founded.
- Funding First funding round of $85.0M.
- Funding Latest funding round, Series C, of $325.4M.
Competitors of ArsenalBio
ArsenalBio has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of ArsenalBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ArsenalBio
The website of ArsenalBio (arsenalbio.com) receives about 5.8K visits a month and ranks #2,220,109 among all websites worldwide, #3,025 in Biotechnology and Pharmaceuticals.
- Monthly visits5.8K
▼ 33.5% vs previous month
- Unique visitors3.9K
per month
- Global rank#2,220,109
among all websites
- Category rank#3,025
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit2.3
- Average visit9 sec
- DevicesDesktop 36% · Mobile 64%
Top companies in Cell Therapy
3 companies that operate in the same segment as ArsenalBio (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arsenalbio
Complete news archive for ArsenalBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ArsenalBio
ArsenalBio was founded in 2019.
ArsenalBio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Ken Drazan is the CEO of ArsenalBio, as recorded in our data. They have also founded this company.
ArsenalBio is a funded company, having raised a total of $631.16M across 3 funding rounds to date. The company's 1st funding round was a Series A of $85M, raised on Oct 2019.
ArsenalBio has 178 employees.
Developer of immune cell therapies. The company develops programmable immune cell therapies using cloud computing, genome engineering, and synthetic immunology technologies.
ArsenalBio offers AB-4000 Series.
ArsenalBio has 23 investors. Key investors include Kleiner Perkins, T. Rowe Price, University of California, Arch Venture Partners, and Bristol-Myers Squibb.
ArsenalBio operates through Arsenal Biosciences, Inc..